Immunotherapeutic strategies targeting stimulatory TNFRSF receptors to promote anti-tumor immune responses have tremendous potential and CD27 is an important candidate due to its unique role in both initiating as well as maintaining T cell responses. This evidence concerns the gene CD27 and neoplasm.